BiotechTube

NNZ-2566 + Placebo

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Fragile X Syndrome

Conditions

Fragile X Syndrome

Trial Timeline

Jan 1, 2014 → Oct 1, 2015

NCT ID
NCT01894958

About NNZ-2566 + Placebo

NNZ-2566 + Placebo is a phase 2 stage product being developed by Neuren Pharmaceuticals for Fragile X Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT01894958. Target conditions include Fragile X Syndrome.

Hype Score Breakdown

Clinical
12
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (8)

NCT IDPhaseStatus
NCT02715115Phase 2Completed
NCT02100150Phase 2Terminated
NCT01894958Phase 2Completed
NCT01703533Phase 2Completed
NCT01366820Phase 2Completed
NCT01420042Phase 1Completed
NCT00805818Phase 2Completed
NCT00961779Phase 1Completed

Competing Products

14 competing products in Fragile X Syndrome

See all competitors
ProductCompanyStageHype Score
CTH120Connecta TherapeuticsPhase 1
19
AFQ056NovartisPhase 1
29
AFQ056NovartisPhase 2/3
30
AFQ056 + PlaceboNovartisPhase 2
35
AFQ056 + PlaceboNovartisPhase 2
35
AFQ056NovartisPhase 2
27
AFQ056 + PlaceboNovartisPhase 2
35
AF056 + PlaceboNovartisPhase 2
35
Placebo + RO4917523 + RO4917523RochePhase 2
35
Placebo (for RO4917523 ascending doses) + Placebo (for RO4917523 fixed dose) + RO4917523 + RO4917523RochePhase 2
35
Placebo + RO4917523 0.5 mg + RO4917523 1.5 mgRochePhase 2
35
CBD Oral Solution + PlaceboJazz PharmaceuticalsPhase 2
39
CBD Oral Solution (eCBD system Target) + PlaceboJazz PharmaceuticalsPhase 2
39
Low dose of MRM-3379 + Middle Dose of MRM-3379 + High dose of MRM-3379 + Placebo + Low dose of MRM-3379 Open-LabelMirum PharmaceuticalsPhase 2
39